AR032989A1 - Una composicion farmaceutica util para el tratamiento del cancer - Google Patents

Una composicion farmaceutica util para el tratamiento del cancer

Info

Publication number
AR032989A1
AR032989A1 ARP020100914A ARP020100914A AR032989A1 AR 032989 A1 AR032989 A1 AR 032989A1 AR P020100914 A ARP020100914 A AR P020100914A AR P020100914 A ARP020100914 A AR P020100914A AR 032989 A1 AR032989 A1 AR 032989A1
Authority
AR
Argentina
Prior art keywords
treatment
cancer
pharmaceutical composition
composition useful
apidophyllotoxins
Prior art date
Application number
ARP020100914A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of AR032989A1 publication Critical patent/AR032989A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se provee una combinacion antitumoral que comprende un derivado del estilbeno y un compuesto anticarcinogeno seleccionado entre el grupo consistente en taxanos, agentes alquilantes, antimetabolitos, alcaloides de la vinca, apidofilotoxinas y antibioticos como componentes activos. También se proveen métodos para utilizar estas preparaciones farmacéuticas para el tratamiento de carcinomas solidos y similares.
ARP020100914A 2001-03-15 2002-03-14 Una composicion farmaceutica util para el tratamiento del cancer AR032989A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27562701P 2001-03-15 2001-03-15

Publications (1)

Publication Number Publication Date
AR032989A1 true AR032989A1 (es) 2003-12-03

Family

ID=23053164

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100914A AR032989A1 (es) 2001-03-15 2002-03-14 Una composicion farmaceutica util para el tratamiento del cancer

Country Status (38)

Country Link
US (4) US20020183266A1 (es)
EP (1) EP1439839B8 (es)
JP (1) JP4991107B2 (es)
KR (1) KR100849610B1 (es)
CN (2) CN1935134B (es)
AR (1) AR032989A1 (es)
AT (1) ATE433750T1 (es)
AU (1) AU2002304574B2 (es)
BR (1) BR0208017A (es)
CA (2) CA2470484C (es)
CY (1) CY1109364T1 (es)
CZ (1) CZ302451B6 (es)
DE (1) DE60232673D1 (es)
DK (1) DK1439839T3 (es)
EA (1) EA006316B1 (es)
EC (1) ECSP034766A (es)
ES (1) ES2327617T3 (es)
HK (1) HK1067039A1 (es)
HR (1) HRPK20030734B3 (es)
HU (1) HU228510B1 (es)
IL (2) IL157891A0 (es)
MA (1) MA27000A1 (es)
ME (2) MEP16208A (es)
MX (1) MXPA03007552A (es)
NO (1) NO332661B1 (es)
NZ (1) NZ527526A (es)
PE (1) PE20020909A1 (es)
PL (1) PL205728B1 (es)
PT (1) PT1439839E (es)
RS (1) RS50682B (es)
SI (1) SI1439839T1 (es)
SK (1) SK287908B6 (es)
TN (1) TNSN03060A1 (es)
TW (1) TWI306028B (es)
UA (1) UA75127C2 (es)
UY (1) UY27208A1 (es)
WO (2) WO2002074229A2 (es)
ZA (1) ZA200306789B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE328599T1 (de) * 1998-04-03 2006-06-15 Ajinomoto Kk Antitumorale mittel
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
GB0410817D0 (en) * 2004-05-14 2004-06-16 Angiogene Pharm Ltd Vascular damaging therapy
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN1319978C (zh) * 2005-04-06 2007-06-06 西南合成制药股份有限公司 康布瑞汀化合物的制备方法
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
US20080104512A1 (en) * 2006-10-31 2008-05-01 Motorola, Inc. Method and apparatus for providing realtime feedback in a voice dialog system
US20090192098A1 (en) * 2007-11-21 2009-07-30 Oxigene, Inc. Method for treating hematopoietic neoplasms
US20090209496A1 (en) * 2008-02-15 2009-08-20 David Chaplin Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2939665B1 (fr) * 2008-12-12 2011-10-07 Sanofi Aventis Combinaison antitumorale associant l'ave8062a et le docetaxel
FR2945210B1 (fr) * 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib
EP2397135A1 (en) 2010-06-18 2011-12-21 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
MX2012014732A (es) 2010-06-18 2013-01-22 Sanofi Sa Una combinacion antitumoral que comprende ombrabulina un derivado de taxano y un derivado de platino.
EP2481404A1 (en) 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2407161A1 (en) 2010-07-13 2012-01-18 Sanofi An antitumoral combination comprising ombrabulin and bevacizumab
FR2968557A1 (fr) 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
EP3337495A4 (en) 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
US9980953B2 (en) * 2016-09-26 2018-05-29 Chong Kun Dang Pharmaceutical Corp. Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US5430062A (en) * 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
TW325458B (en) * 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US5731353A (en) * 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
TW334418B (en) * 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
ATE328599T1 (de) * 1998-04-03 2006-06-15 Ajinomoto Kk Antitumorale mittel
US6242770B1 (en) * 1998-08-31 2001-06-05 Gary Bela Bronner Diode connected to a magnetic tunnel junction and self aligned with a metallic conductor and method for forming the same
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
ATE342054T1 (de) * 1999-04-14 2006-11-15 Dana Farber Cancer Inst Inc Verfahren und zusammansetzung zur behandlung von krebs
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
EP1333820A2 (en) * 2000-10-27 2003-08-13 Aventis Pharma S.A. A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
JP2004523517A (ja) * 2000-12-22 2004-08-05 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍増殖および転移を調節するための方法
US6466448B1 (en) * 2001-06-11 2002-10-15 Network Appliance, Inc. Riser board retaining and air ducting structure for printed circuit boards

Also Published As

Publication number Publication date
ECSP034766A (es) 2003-10-28
US6933320B2 (en) 2005-08-23
HU228510B1 (en) 2013-03-28
HUP0600233A2 (en) 2008-06-30
CZ20032476A3 (en) 2004-07-14
BR0208017A (pt) 2004-12-07
KR20040067866A (ko) 2004-07-30
AU2002304574A1 (en) 2004-05-13
IL157891A0 (en) 2004-03-28
US20070149476A1 (en) 2007-06-28
MA27000A1 (fr) 2004-12-20
CA2470484C (en) 2009-10-13
HRP20030734A2 (en) 2005-06-30
CN1935134A (zh) 2007-03-28
NO332661B1 (no) 2012-11-26
US20030060429A1 (en) 2003-03-27
HUP0600233A3 (en) 2010-03-29
CN1547471A (zh) 2004-11-17
EA006316B1 (ru) 2005-10-27
ATE433750T1 (de) 2009-07-15
EP1439839B1 (en) 2009-06-17
PL374406A1 (en) 2005-10-17
CA2470484A1 (en) 2004-05-06
DK1439839T3 (da) 2009-10-05
HRPK20030734B3 (en) 2006-11-30
NZ527526A (en) 2006-11-30
JP4991107B2 (ja) 2012-08-01
CN1935134B (zh) 2010-12-15
MEP16208A (en) 2010-06-10
EP1439839B8 (en) 2010-09-01
AU2002304574B2 (en) 2005-09-15
MXPA03007552A (es) 2004-10-15
CY1109364T1 (el) 2014-07-02
US20050075295A1 (en) 2005-04-07
NO20034022D0 (no) 2003-09-11
US20020183266A1 (en) 2002-12-05
UY27208A1 (es) 2002-08-30
NO20034022L (no) 2003-09-11
KR100849610B1 (ko) 2008-07-31
EP1439839A1 (en) 2004-07-28
SK11552003A3 (sk) 2004-03-02
ZA200306789B (en) 2005-02-23
WO2004037258A1 (en) 2004-05-06
ES2327617T3 (es) 2009-11-02
PL205728B1 (pl) 2010-05-31
RS50682B (sr) 2010-06-30
YU71303A (sh) 2006-08-17
WO2002074229A2 (en) 2002-09-26
IL157891A (en) 2010-06-16
SI1439839T1 (sl) 2011-09-30
TNSN03060A1 (en) 2005-12-23
CN1290504C (zh) 2006-12-20
CA2673449A1 (en) 2004-05-06
PE20020909A1 (es) 2002-12-09
HK1067039A1 (en) 2005-04-01
CA2673449C (en) 2011-10-18
UA75127C2 (en) 2006-03-15
SK287908B6 (sk) 2012-03-02
JP2005522527A (ja) 2005-07-28
EA200301015A1 (ru) 2004-08-26
PT1439839E (pt) 2009-09-03
ME00056B (me) 2010-06-10
TWI306028B (en) 2009-02-11
CZ302451B6 (cs) 2011-05-25
DE60232673D1 (de) 2009-07-30

Similar Documents

Publication Publication Date Title
AR032989A1 (es) Una composicion farmaceutica util para el tratamiento del cancer
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
RU2011138835A (ru) Применение производного рапамицина
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
PA8588601A1 (es) Administracion combinada de una indolinona junto a un agente quimioterapeutico para el tratamiento de enfermedades de proliferacion celular
ECSP055528A (es) Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco
UY26130A1 (es) Compuestos para tratar la obesidad
PE20020348A1 (es) Exemestano como agente quimiopreventivo
DE60228484D1 (de) Cytotoxische mittel
DK0934065T3 (da) Hidtil ukendte cruptophycinderivater som antieoplastiske midler
AR032432A1 (es) Combinaciones oncoliticas para el tratamiento de cancer
UY29069A1 (es) Uso de compuestos tpo miméticos y composiciones farmacéuticas para el tratamiento de la anemia
AR026911A1 (es) Preparado farmaceutica para el tratamiento de afecciones tumorales
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
DE602004022578D1 (de) Antitumorale terpen-verbindungen
AR030750A1 (es) 1-amino-alquilciclohexanos como agentes tripanocidas
CR6513A (es) Polimorfos de un citrato de azobiciclo 2,2,2, oct-3-ilamina cristalino y sus composiciones farmeceuticas
AR005730A1 (es) Forma de fanciclovir, procedimiento para prepararla, composiciones farmaceuticas que la contienen y metodo para el tratamiento o profilaxis deinfecciones virales y el uso de dicha forma -fanciclovir monoidrato.
GT200100099A (es) Derivados de higromicina a.
AR027037A1 (es) Compusto y metodo para el tratamiento del dolor
AR036257A1 (es) Sulfamatos de 2-alcoxiestradiol de accion antitumoral

Legal Events

Date Code Title Description
FB Suspension of granting procedure